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ABSTRACT
Introduction: Lower respiratory tract infection
(LRTI) is the leading cause of infant mortality
globally in post-neonatal infants (i.e.,
28–364 days of age). Respiratory syncytial virus
(RSV) is the most commonly identified
pathogen for infant LRTI and is the second
most important cause of death in post-neonatal
infants. Despite 50 years of RSV vaccine
research, there is still no approved vaccine.
Therefore, passive immunity with the
monoclonal antibody palivizumab is the sole
regulatory-approved option for the prevention
of serious LRTI caused by RSV in pediatric
patients at high risk of RSV disease.
Methods: We conducted a comprehensive
systematic literature review of randomized
controlled trials (RCTs), open-label non-
comparative clinical trials, and prospective
observational studies/registries, and summarized
the evidence related to the safety, efficacy, and
effectiveness of palivizumab.
Results: The efficacy of palivizumab, as
measured by the relative reduction in RSV-
related hospitalization rate compared with
placebo ranged from 39% to 78% (P\0.05) in
the 2 pivotal RCTs. A meta-analysis of the RSV-
related hospitalization rate from 5 randomized
placebo-controlled trials yielded an overall odds
ratio of 0.41 (95% CI, 0.31–0.55) in favor
of palivizumab prophylaxis over placebo
(P\0.00001). Low rates of RSV-related
hospitalizations were observed in palivizumab
recipients consistently over time in more
than 42,000 pediatric subjects across 7 RCTs, 4
open-label non-comparative trials, and 8
observational studies/registries conducted in
34 countries. In addition, among palivizumab-
prophylaxed subjects with breakthrough RSV
LRTI, rates of intensive care unit admission and
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mechanical ventilation from RSV hospitalization
also were low and consistent across studies. With
respect to safety, no differences were observed
between palivizumab and placebo in the blinded
RCTs.
Conclusion: Rates of RSV hospitalizations and
RSV hospitalization-related endpoints in
pediatric subjects who received prophylaxis
with palivizumab were low and constant over
time and across RCTs, open-label non-
comparative trials, and observational studies/
registries.
Keywords: Efficacy; Palivizumab; Respiratory
syncytial virus; Safety; Serious lower
respiratory tract infection; Systematic review
INTRODUCTION
Respiratory syncytial virus (RSV) is one of the
most common causes of viral lower respiratory
tract infection (LRTI) in children worldwide and
is associated with considerable morbidity and
mortality [1]. LRTI was the leading cause of
infectious disease hospitalizations among
infants according to a recent analysis of
hospital admissions in the United States (US)
[2]. Globally, LRTI is the leading cause of death
among post-neonatal infants (i.e., 28–364 days
of age). In 2010, 20.1% of the 2 million global
deaths among post-neonatal infants were
caused by LRTI; malaria was the second most
common cause, accounting for 11.8% of post-
neonatal mortality [3]. The most commonly
identified pathogen of LRTI in post-neonatal
infants is RSV [3]. These findings highlight the
significance of the malaria parasite Plasmodium
falciparum and RSV as the two most important
pathogen-specific causes of global mortality in
this age group [3]. In addition to severe acute
disease, evidence also suggests that children
who had severe RSV infection early in life are
more likely to develop subsequent wheezing
during early childhood [4] and hyperreactive
airways and asthma later in life [5].
RSV is a typically seasonal virus with
outbreaks spanning from late autumn through
early spring in temperate climates and
throughout the rainy season in tropical
climates. RSV is an extremely infectious virus,
such that almost all children have contracted
RSV by the age of 2 years [6]. Furthermore, re-
infections are frequent because previous
infection with RSV does not confer long-term
immunity [7]. RSV disease manifestations in
infants range from mild upper respiratory tract
infection to respiratory failure. Certain high-risk
groups, including premature infants; infants
with underlying medical conditions such as
chronic lung disease of prematurity (CLDP),
also known as bronchopulmonary dysplasia
(BPD); hemodynamically significant congenital
heart disease (CHD); immunocompromised
conditions; and severe neuromuscular disease,
are more prone to serious disease due to RSV
with higher hospitalization and mortality rates
than those without these conditions [8, 9].
RSV is classified in the Pneumovirus genus of
the Paramyxoviridae family of RNA viruses.
RSV is an enveloped virus, containing a
negative-sense, single-stranded RNA genome
comprising *15,000 nucleotides that encode
11 viral proteins [10]. The antigenicity of
RSV is determined by two transmembrane
glycoproteins. The RSV G glycoprotein is
responsible for viral attachment to cells, and
the RSV F glycoprotein promotes fusion of viral
and cell membranes [10, 11]. Both the G and F
glycoproteins are targets for RSV-neutralizing
antibodies. RSV is classified in A and B
subgroups, based on antigenic differences in
the G protein [12].
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The current goal of RSV vaccine
development is the prevention of serious RSV
disease in the population at highest risk, i.e.,
young infants [13]. In the absence of an
effective, curative treatment for RSV infection
[13], disease management is guided by the
severity of respiratory distress and primarily
involves supportive strategies such as hydration
and oxygenation [6, 14]. An effective vaccine
against RSV would be expected to decrease the
global health burden and is urgently needed;
however, one does not currently exist owing to
the complexity and inherent challenges of RSV
vaccine development. For example, neonates at
risk for developing RSV disease have not been
able to mount a strong immune response
following administration of vaccines in
development. Strategies for vaccinating
pregnant women have been proposed with the
intent of maternal transfer of anti-RSV
antibodies to the fetus [13]. However, this
approach may not provide adequate
protection for very premature infants, who
may not benefit from immunity afforded by
maternal immunization because transplacental
transport of antibodies occurs during the third
trimester [15]. Efficacy was not demonstrated in
a series of trials in the 1960s that evaluated a
formalin-inactivated whole virus RSV vaccine.
Ironically, respiratory disease from natural RSV
infection was more severe in children who
received the experimental vaccine compared
with children who did not receive the vaccine
[16–18]. Moreover, in 1 trial in which 31 infants
2–7 months of age received C1 injection of an
experimental antigenic inactivated RSV
vaccine, 2 deaths were attributed to the
exaggerated clinical course of disease during
RSV infection and were deemed to be associated
with the vaccine [17]. Although the biologic
cause leading to this phenomenon was never
definitively determined, these discouraging
results led to a more measured and
conservative approach in the development of
an RSV vaccine. There are currently a number of
vaccine candidates in preclinical or phase I or II
clinical development [13]; however, for the time
being, passive immunity is the only means
available to help reduce hospitalizations due to
severe RSV disease.
The current prophylactic approach is passive
immunity with antibodies. The first of such
products was a polyclonal immunoglobulin
formulation enriched for RSV-neutralizing
antibody (RespiGam; MedImmune, LLC,
Gaithersburg, MD, USA) that reduced
moderate or severe LRTI disease caused by RSV
by 72% [19] and, in 1996, was the first
prophylactic agent approved by the US Food
and Drug Administration (FDA) for use in high-
risk children. However, its use was hampered
by the requirement that large volumes
of immunoglobulin be administered by
intravenous (IV) infusion over several hours
on a monthly basis throughout the RSV season.
While RespiGam was effective in reducing the
incidence of RSV-related hospitalization in both
preterm infants and infants with BPD [20],
RespiGam did not significantly reduce the
RSV-related hospitalization rate in children
with CHD and was associated with increased
cyanotic episodes and cardiac-related deaths in
children with cyanotic CHD [21].
Research efforts were then directed toward
the development of alternative agents with less
complex methods of administration and
potentially increased efficacy. The use of
RespiGam was discontinued in 2003 following
the 1998 approval of palivizumab (Synagis;
MedImmune, LLC, Gaithersburg, MD, USA) and
the demonstration that a monoclonal antibody
could be efficacious against an infectious agent.
Compared with the IV administration of
RespiGam, palivizumab is administered via an
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intramuscular (IM) injection. The evolution
from polyclonal IV to monoclonal IM
injection eliminated concerns for transmission
of bloodborne pathogens as well as potential
fluid overload. Palivizumab is a humanized
monoclonal antibody specific for the antigenic
site A on the highly conserved F protein on the
surface of RSV. Palivizumab has potent
neutralizing and fusion-inhibiting activity
against RSV subgroups A and B [22].
Depending on the patient population, the
efficacy of palivizumab ranged from a 39% to
78% reduction in RSV-related hospitalization
compared with placebo in the 2 pivotal
randomized controlled trials (RCTs) [23, 24].
Palivizumab was approved by the FDA in 1998
for use in reducing the risk of serious LRTI
disease caused by RSV in children at high risk of
RSV disease. Populations where efficacy has
been established are children with BPD, CHD,
and premature infants (B35 weeks gestational
age [GA]) [23, 24]. Prophylaxis with
palivizumab begins before the expected start
of the RSV season, with additional doses given
monthly throughout the season. In its original
formulation, palivizumab was supplied as
a lyophilized product that required
reconstitution with sterile water for IM
injection. This process took *20 min. A liquid
formulation of palivizumab was subsequently
developed, precluding the need for
reconstitution. Bioequivalence between the
lyophilized and liquid formulations was
demonstrated in children B6 months of age
with a history of prematurity [25]. The liquid
formulation was first approved in 2004 in the
US and is also currently available in Japan;
broad global filings and approvals of the liquid
preparation are ongoing.
We conducted a timely and comprehensive
systematic review of RCTs, open-label non-
comparative clinical trials, and prospective
observational studies/registries to summarize
and describe the existing evidence related to
the safety, efficacy, and effectiveness of
palivizumab for reducing the risk of serious




We performed a literature search in MEDLINE
(via PubMed), Embase, BIOSIS Previews, and
Derwent Drug File using the following general
terms and limits: ‘‘respiratory syncytial virus’’
AND ‘‘palivizumab OR Synagis’’ AND
‘‘premature’’ AND ‘‘congenital heart disease OR
bronchopulmonary dysplasia OR chronic lung
disease’’ AND ‘‘efficacy OR effect’’ AND ‘‘limits:
human, premature/preterm (up to 35 weeks),
English, clinical trial OR prospective
observational study’’. Separate literature
searches were performed for RCTs and
prospective observational studies/registries (see
the Appendix in the electronic supplementary
material). Published articles and congress
abstracts indexed from January 1996 through
July 2013 in MEDLINE and from January 1996
through August 2013 in the other databases
were searched. References contained in any
systematic reviews and meta-analyses found
through the literature search were also
reviewed to identify additional relevant studies
not already captured.
Study Selection
All results from the literature search were
reviewed at the abstract level by three authors
(LKT, GN, CW). Inclusion criteria for the
systematic review were studies reporting the
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primary outcome of the RSV-related
hospitalization rate in children at high risk of
severe RSV disease who received C1 injection
of palivizumab at 15 mg/kg. High risk was
defined as children with a history of
prematurity (B35 weeks GA) or children with
BPD or hemodynamically significant CHD.
Retrospective studies, epidemiologic studies,
case reports, letters, comments, editorials,
reviews, and meta-analyses were excluded
from the systematic review. Results from the
literature search and cross-referenced
publications found from systematic reviews or
meta-analyses that appeared to meet these
selection criteria were independently reviewed
at the full-text level by the same three authors;
any disagreements over whether to include a
study in the systematic review were resolved by
discussion among the authors.
Data Analyses
A meta-analysis of the primary outcome of RSV-
related hospitalization was conducted for the
randomized placebo-controlled trials included
in this systematic review. A fixed-effects meta-
analysis was used (Mantel–Haenszel method) to
assess the odds ratio (OR) of palivizumab
compared with placebo using Review Manager
Version 5.3 (The Nordic Cochrane Centre,
The Cochrane Collaboration, Copenhagen,
Denmark). Because of the heterogeneity of the
study populations and methodologic variability
among the studies, no formal combined
statistical analyses were performed across the
other types of studies or for any of the other
major outcomes (i.e., RSV hospitalization-
related outcomes, drug-related adverse events
[AEs] and serious adverse events [SAEs]).
Therefore, we describe the results of the
included studies separately.
Statement of Ethics Compliance
The analysis in this article is based on
previously published studies and does not
involve any new studies of human subjects
performed by any of the authors.
RESULTS
A total of 347 publications were retrieved from
the literature search and reviewed at the
abstract level (Fig. 1); 314 abstracts were
rejected for not meeting the selection criteria
or for duplicative reporting. Thirty-three
publications from the literature search and an
additional 14 cross-referenced publications
were reviewed at the full-text level, with 26
Fig. 1 Study selection diagram. Asterisk indicates three
articles reported results on different time periods and
subject populations from the same registry. RSV
Respiratory syncytial virus
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being rejected after author review for the
reasons shown in Fig. 1. The final 21
publications included in this review originated
from 7 RCTs, 4 open-label non-comparative
trials, and 8 prospective observational studies or
registries, with 3 publications [26–28] reporting
results from different time periods or
populations of the same registry. The analysis
comprises more than 42,000 high-risk infants/
children from 34 countries. Characteristics of
the studies included in this systematic review
are described in Appendix Table A1.
Efficacy: Reduction of RSV-Related
Hospitalization
Efficacy of Palivizumab in Randomized,
Placebo-Controlled Clinical Trials
Palivizumab administered at 15 mg/kg monthly
during the RSV season was initially evaluated as
a pre-approval IV formulation in a phase I/II,
randomized, double-blind, placebo-controlled
trial conducted from 1995 to 1996 in the US
[29]. In this trial, the incidence of RSV-related
hospitalization in children B24 months of age
with BPD or infants B6 months of age who were
born at B35 weeks GA was 10.0% (2/20) with
placebo and 0% (0/22) with palivizumab
(Table 1).
Subsequent studies of palivizumab included
in this review were performed using the IM
injection formulation. The efficacy of
palivizumab as measured by the reduction in
the RSV-related hospitalization rate was
subsequently assessed in two large,
randomized, double-blind, placebo-controlled
trials [23, 24].
The IMpact-RSV trial was conducted during a
single RSV season from 1996 to 1997 and
studied a total of 1,502 children B24 months
of age with BPD or infants B6 months of age
who were born prematurely (B35 weeks GA) in
the US, Canada, and the United Kingdom (UK)
[24]. In children who were premature or who
had BPD, palivizumab reduced RSV-associated
hospitalization by 55%, from an incidence of
10.6% (53/500) in children receiving placebo
versus 4.8% (48/1,002) in children receiving
palivizumab (Table 1; Fig. 2). In addition, the
reduction of RSV-related hospitalization was
observed both in children with BPD (34/266
[12.8%] with placebo versus 39/496 [7.9%] with
palivizumab; 39% relative reduction) and in
premature infants without BPD (19/234 [8.1%]
with placebo versus 9/506 [1.8%] with
palivizumab; 78% relative reduction; Table 1).
The Cardiac trial was conducted over 4
consecutive seasons from 1998 to 2002 in a
total of 1,287 children B24 months of age with
hemodynamically significant CHD in the US,
Canada, Sweden, Germany, France, the UK, and
Poland [23]. In this trial, palivizumab reduced
RSV-associated hospitalization by 45% in
children with hemodynamically significant
CHD from an incidence of 9.7% (63/648) in
children receiving placebo versus 5.3% (34/639)
in children receiving palivizumab (Table 1;
Fig. 2) [23]. Although the Cardiac study was not
powered for subgroup analyses, there were
reductions in RSV-related hospitalization rates
in both cyanotic and acyanotic children
(Table 1; Fig. 2).
A recent prospective RCT (ClinicalTrials.gov
#ISRCTN73641710) conducted from 2008 to
2010 in the Netherlands further defined the
efficacy of palivizumab in premature infants by
GA [30]. In 429 preterm infants born at
33–35 weeks GA without underlying health
conditions, the incidence of RSV-associated
hospitalization was reduced by 82%, from an
incidence of 5.1% in those receiving placebo (11/
215) versus 0.9% in those receiving palivizumab
(2/214; P = 0.01; Table 1) [30]. In addition, RSV
infection requiring medical attention but not
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hospitalization was also significantly reduced by
81%, from an incidence of 4.7% in recipients of
placebo (10/215) versus 0.9% in recipients of
palivizumab (2/214; P = 0.02) [30].
More recently, Tavsu et al. [31] conducted a
study from 2009 to 2011 in 80 infants with a GA
of \32 weeks in Turkey. These infants were
randomized to receive prophylaxis with
palivizumab (study group, n = 39) or no
prophylaxis (control group, n = 41). The
incidence of RSV-related hospitalization was
significantly lower in the study group than the
Fig. 2 RSV-related hospitalization rates in the large
randomized controlled trials: a IMpact-RSV [24],
b Carbonell-Estrany et al. [70], c MAKI [30], d Tavsu
et al. [31], e Cardiac [23], and f Feltes et al. [71] studies.
Relative reduction rate compared with placebo is shown as
;%. Asterisk indicates without BPD/CLDP. BPD
Bronchopulmonary dysplasia, CHD hemodynamically
signiﬁcant congenital heart disease, CLDP chronic lung
disease of prematurity, GA gestational age, mo months, RSV
respiratory syncytial virus, wk weeks, y years
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control group both in the year of prophylaxis
and the following year (0% vs. 24.4% in both
years; P = 0.001; OR 1.32 [95% CI, 1.11–1.57];
Table 1).
Combining the results from these 5
randomized placebo-controlled trials in a meta-
analysis of the RSV-related hospitalization rate
yielded an overall OR of 0.41 (95% CI, 0.31–0.55)
in favor of palivizumab prophylaxis over placebo
(P\0.00001; Fig. 3).
Efficacy of Palivizumab in Prospective, Open-
Label, Non-Comparative Clinical Trials
During the 1998–1999 RSV season, Abbott
Laboratories (now AbbVie) conducted an
Expanded Access Trial, which was a phase III
and IV, multicenter, single-arm, open-label
study to collect additional safety data on
palivizumab-prophylaxed infants in countries
where palivizumab was not yet available [32].
The study included preterm children born at
B35 weeks GA who were B6 months old at
enrollment, and children with BPD. A total of
565 children were enrolled in 16 countries in
Europe, North America, and the Middle East,
with 530 completing the study. Fifty-one (65%)
of 78 hospitalizations during the study were due
to respiratory causes. Among 29 cases tested for
RSV, 7 were positive and 22 were negative.
When the RSV test positivity rate (24%) was
applied to the 22 untested respiratory cases, the
estimated RSV hospitalization rate was 2.1%
(12/565; Table 2).
Many guidelines are aligned with the
licensed indications of palivizumab and
recommend that children with BPD requiring
medical intervention at the onset of the RSV
season receive prophylaxis up to the age of
24 months at the start of the RSV season (US,
UK, Canada, Spain, and Germany) [33–37].
Therefore, some children with severe BPD will
receive prophylaxis for more than one RSV
season. A multicenter, open-label study was
conducted in 7 European countries and Canada
in 134 children \2 years old at risk for serious
RSV infection, primarily because of BPD [38].
Seventy-one subjects without previous
palivizumab exposure (mean age 8 months)
and 63 subjects exposed to palivizumab during
the previous season (mean age 16 months)
received prophylaxis with palivizumab during
the 1999–2000 RSV season. Five subjects (3.7%)
were hospitalized for RSV-related respiratory
illness overall, with no differences in incidence
observed between the first-season exposure (1
[1.4%]) and second-season exposure subjects (4
[6.3%]; P = 0.187; Table 2) [38]. This study
Fig. 3 Meta-analysis of RSV-related hospitalization in the randomized, placebo-controlled trials. M–H Mantel–Haenszel
method, RSV respiratory syncytial virus
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demonstrated a risk of serious RSV disease
persisting beyond the first year of life in
children with BPD.
Premature infants, regardless of their GA, are
at high risk for serious RSV disease. As the subset
of infants born at 29–32 weeks GA without
CLDP was not specifically evaluated in the
IMpact-RSV study [24], the PROTECT
(Palivizumab RSV Open-label Trial of
Effectiveness and Clinical Tolerability) study
[39] was conducted to gather additional data in
this patient population. During the 2000–2001
season, 285 subjects were enrolled from 16
European countries and Saudi Arabia. Of 20
(7%) hospitalizations for respiratory-related
infections, 5 (1.8%) subjects were hospitalized
for RSV-positive LRTI (Table 2). This RSV
hospitalization rate is comparable to the
incidence observed in the IMpact-RSV study
[24].
Prior to palivizumab approval in the Russian
Federation, a multicenter, prospective, open-
label, non-comparative clinical study
(ClinicalTrials.gov #NCT01006629) was
conducted in high-risk children [40]. The
study included children at high risk of serious
RSV disease, defined as infants born at
B35 weeks GA who were B6 months old at
enrollment or children B24 months old with
a clinical diagnosis of BPD and/or
Table 2 RSV-associated hospitalizations and related efﬁcacy endpoints in the open-label non-comparative studies














































5/134 (3.7) NA NA NA NA
Detailed characteristics of these studies are presented in Appendix Table A1
BPD Bronchopulmonary dysplasia, CLDP chronic lung disease of prematurity, GA gestational age, ICU intensive care unit,
NA not available, RSV respiratory syncytial virus
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hemodynamically significant CHD. One
hundred subjects received C1 injection of
palivizumab during the 2009–2010 RSV
season, and 94 completed their dosing
schedule. There were no RSV hospitalizations
(Table 2) or deaths. Of the seven subjects
hospitalized for respiratory/cardiac conditions,
six were tested for RSV and all test results were
negative.
RSV-Related Hospitalizations
in Prospective Observational Studies/
Registries
Prospective observational studies and registries
provide valuable information regarding the use
of palivizumab in routine clinical practice and
have accumulated a wealth of real-world
information on the clinical effectiveness of
RSV immunoprophylaxis with palivizumab.
Over 13 years (1999–2011) and across 8
observational studies/registries in Spain,
France, Germany, Canada, and the US, RSV-
related hospitalization rates for prophylaxed
infants/children ranged from 0.8% to 7.6%
[26, 41–46] (Table 3). The highest rate (7.6%)
was observed in a French registry [42], whereas
the rate ranged from 0.8% to 3.95% in the
other observational studies/registries [26, 41,
43–46]. The higher RSV hospitalization rate
observed in the French registry may have been
driven by enrollment of a very-high-risk
population where 88% of subjects in the
cohort had a GA B32 weeks, 52% were
children born before 28 weeks GA, and the
rate of BPD was 81%. In comparison, the rate
of BPD among children enrolled in the
IMpact-RSV study was 50% [24, 42]. In
general, RSV-related hospitalization rates were
similar for palivizumab recipients in the




Although prophylaxis with palivizumab reduces
the incidence of RSV-related hospitalizations,
some children still develop breakthrough
disease and require hospitalization. Tables 1, 2
and 3 illustrate the effect of palivizumab
prophylaxis on RSV hospitalization-related
endpoints. These are important surrogate
markers of disease severity and include
duration of RSV-related hospitalization,
intensive care unit (ICU) admission, oxygen
supplementation, and mechanical ventilation.
In the IMpact-RSV study, children with BPD
or a history of prematurity randomized to
receive prophylaxis with palivizumab spent
significantly fewer days in the hospital and
required fewer days of supplemental oxygen
during RSV hospitalization compared with
children randomized to receive placebo (all
P\0.001; Table 1) [24]. The overall
requirement for ICU admission and/or
mechanical ventilation was low and was
influenced by a small number of children with
complex underlying disease. Differences in the
incidence of and days on mechanical
ventilation did not differ significantly between
groups [24].
Children with hemodynamically significant
CHD receiving palivizumab prophylaxis also
had significantly fewer days of RSV-related
hospitalization (P = 0.003) and significantly
fewer days with increased oxygen requirement
compared with children receiving placebo
(P = 0.014; Table 1) [23]. Other secondary
efficacy endpoints, including incidence and
days in the ICU and days on mechanical
ventilation were not significant but did exhibit
trends favoring palivizumab over placebo.
The results of the RSV hospitalization-related
outcomes from the non-comparative trials and
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observational studies are similar to the results
from the RCTs. For example, the percentage of
subjects with BPD or prematurity who required
mechanical ventilation was 0.7% in the open-
label PROTECT trial (Table 2) conducted in 16
European countries and Saudi Arabia [39] and
0.1–0.8% in 2 observational studies (Table 3)
conducted in Spain and the US [27, 28, 45]
compared with 0.3–1.3% in the RCTs (Table 1).
In the only observational study to include case
controls, there was a statistically significant
reduction in RSV hospitalization duration and
numerical decreases in the percentage of
subjects requiring ICU admission or
mechanical ventilation in Spanish subjects
who received prophylaxis with palivizumab
compared with those who did not receive
prophylaxis [45].
Safety and Immunogenicity
The safety data for palivizumab was first
established in 2,789 infants enrolled in the
two registrational randomized placebo-
controlled trials (Table 4) [23, 24]. In the
IMpact-RSV trial, there was no difference in
the placebo and palivizumab groups in the
number of children who had AEs that were
judged to be related to the study drug by the
blinded investigator (10% vs. 11%) [24]. Study
subjects rarely discontinued prophylaxis due to
palivizumab-related AEs (0.3%), and the
incidence of related AEs did not differ
significantly between the placebo and
palivizumab groups. Similar safety findings
were demonstrated in the Cardiac study [23].
The proportion of children with AEs judged by
the blinded investigator to be related to the
study drug was similar between the placebo and
palivizumab groups (6.9% vs. 7.2%). No child
had the study drug discontinued for a related
AE, and the incidence of related SAEs was low
and similar in the placebo and palivizumab
groups (0.5% vs. 0%).
Given that palivizumab has been in clinical
use for 16 years, follow-up clinical trials,
outcome data from several international
registries and post-marketing experience are
consistent with the initial safety profile.
Uncontrolled trial (Table 5) and observational/
registry data (Appendix Table A2) presented in
this systematic review are consistent with
respect to safety findings. Commonly reported
AEs from these data include injection site
reactions and fever. Across RCTs and open-
label non-comparative trials, \2% of AEs led to
study drug discontinuation. In addition,
injection site reactions and severe
thrombocytopenia (platelet count \50,000 per
microliter) have been voluntarily reported
during post-approval use of palivizumab in
over 3.2 million seasonal courses of therapy
(data on file, AbbVie). As these events are
voluntarily reported, their frequency and
causal relationship to palivizumab cannot
always be reliably estimated [22].
SAE reporting was limited in the registries. In
the German Palivizumab Registry [46] conducted
from 2002 to 2007, 10 (0.09%) of 10,686 patients
had C1 SAE considered possibly or probably
related to palivizumab administration: dyspnea/
cyanosis with or without fever (n = 4); skin rash;
thrombocytopenia with petechiae; osteomyelitis
of the distal femur epiphysis; seizure; transient
unresponsiveness; and fever, restlessness, and
feeding difficulties (n = 1 each). From 2005 to
2009, in the total population of 5,286 subjects
enrolled in CARESS [26], 61 SAEs were reported
overall, of which 56 were hospitalizations due to
respiratory infection (including 14 from
breakthrough RSV infection).
Allergic reactions, including very rare cases
of anaphylaxis and anaphylactic shock, have
been reported following palivizumab
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administration in post-marketing settings. In
some cases, fatalities have been reported.
However, because the AEs identified via post-
marketing surveillance are reported voluntarily
from a population of uncertain size, it is not
always possible to reliably estimate their
frequency or establish a causal relationship to
palivizumab exposure.
With repeated exposure, there is a
theoretical concern that recipients of
palivizumab could develop an immune
response to the monoclonal antibody. In the
IMpact-RSV trial, anti-palivizumab antibodies
were assessed before the first and last
palivizumab injections and in a randomized
manner before the second, third, or fourth
injection [24]. In the placebo and palivizumab
groups, titers [1:40 were detected in 2.8% and
1.2% of subjects, respectively. These elevations
generally occurred at single time points and
were not associated with low palivizumab
concentrations or increased AEs. In a French
study conducted to assess the incidence of
anti-palivizumab antibodies and clinical AEs in
children prophylaxed with palivizumab for a
first (no previous palivizumab exposure) versus
a second RSV season, similar serum
concentrations of palivizumab were observed
for both first-season and second-season
subjects, and none had a significant anti-
palivizumab antibody response, defined as a
titer of C1:80 occurring at any time during the
study [38].
DISCUSSION
This systematic review, which assessed results
from 7 RCTs, 4 open-label non-comparative
trials, and 8 prospective observational studies or
registries comprising over 42,000 high-risk
infants/children from 34 countries, found that
palivizumab has shown consistent efficacy or
effectiveness in the reduction of RSV-related
hospitalizations in high-risk populations.
Prophylactic administration of palivizumab
demonstrated an acceptable safety profile in
the identified studies. The data presented in this
systematic review are important for
understanding how palivizumab is currently
used in clinical practice as well as the issues
that remain of interest to the medical
community.
Current Issues in RSV Immunoprophylaxis
Strategies for diminishing the health care
burden from RSV infections include
appropriate and targeted prophylaxis in
children at high risk of severe RSV disease.
Palivizumab is widely approved across Europe,
US, Canada, Asia, and Latin America; however,
in an effort to ensure optimal balance of benefit
and cost from this intervention, clinical
guidelines are country specific and vary with
regard to their recommendations for
prophylaxis in premature infants [33–37, 47–
49]. Compared with term infants, preterm
infants have increased susceptibility to severe
RSV disease, irrespective of the degree of
prematurity, due to interrupted lung
development and an immature immune
system. Alveolar development is not
universally present until 36 weeks GA and
continues following birth through 2 years of
age [50]. While the immune systems of term
infants are aided by maternal transfer of
antibodies across the placenta in the third
trimester, preterm infants are born prior to
completion of this transfer [51]. There is general
agreement that because of the cost of
palivizumab prophylaxis, guidelines should be
put in place to ensure cost-effective use in well-
defined high-risk populations rather than to
152 Infect Dis Ther (2014) 3:133–158
arbitrarily restrict RSV prophylaxis from a
portion of this vulnerable population. Late-
preterm infants account for approximately
three quarters of the preterm birth population
[52], and there is evidence that they experience
increased morbidity and even higher neonatal
mortality compared with near-term or full-term
infants [52–55]; however, the cost-effectiveness
of passive immunoprophylaxis for all late-
preterm infants is questioned. Using risk
factors in this population, cost-effectiveness
can be improved. Robust, validated, evidence-
based risk score models based on defined
variables have been developed in Canada and
Europe [56–58] to identify the late-preterm
infants at the highest risk for RSV-related
hospitalization. These RSV risk score models
have demonstrated cost-effectiveness; thus,
these recommendations have been adopted by
international pediatric advisory committees
[35, 59–62].
Although immunoprophylaxis with
palivizumab has been demonstrated to be
effective in decreasing RSV hospitalization in
high-risk children, hospitalization is only one
of the possible consequences of RSV infection.
More research is needed to examine the
impact of RSV infection on subsequent
morbidity and mortality, to understand the
full impact and burden of RSV infections, and
to clarify additional health benefits and the
value of prophylaxis. There is evidence
suggesting that palivizumab is associated with
reduced infant all-cause mortality [63, 64]. In
addition, prophylaxis with palivizumab has
been associated with a reduction in long-
term respiratory morbidity of severe RSV
infection, such as recurrent wheeze [65, 66].
In a placebo-controlled trial in otherwise
healthy preterm infants of 33–35 weeks GA,
prophylaxis with palivizumab led to a 61%
reduction in wheezing days that was
maintained beyond the end of therapy and
throughout the infants’ first year of life
(P\0.05) [30]. A prospective analysis of
clinical trial data in preterm children
B35 weeks GA reported that palivizumab
exposure may decrease the incidence of
subsequent asthma-like symptoms [65] and
provide a protective effect on recurrent
wheezing in prophylaxed children without a
family history of atopy through 24 months
compared with matched controls [67]. Finally,
a prospective Japanese study in preterm
children born at 33–35 weeks GA found a
lower incidence of recurrent wheezing during
the first 3 years of life after palivizumab
exposure [66]. When considering the impact
of palivizumab on long-term respiratory
effects, it is important to note that the
majority of the evidence is from non-
randomized studies and more research with
well-designed RCTs is needed before definitive
conclusions can be made.
Data concerning the long-term safety of
palivizumab are limited. Considering that
early human life is an important period of
development, research is needed to evaluate the
long-term effects after exposure to palivizumab
in early childhood.
The emergence of viral escape mutants in
response to administration of a monoclonal
antibody such as palivizumab must be
considered. Palivizumab binds to antigenic
site A, a highly conserved region on the
extracellular domain of RSV F, which
encompasses amino acids 262–275. Only
changes in antigenic site A of the F protein
have been demonstrated to confer resistance to
palivizumab [68]. The rate of palivizumab-
resistant mutations is low in both
immunoprophylaxis-naı¨ve patients (\1%) [68]
and in patients experiencing breakthrough RSV
disease while taking palivizumab (6.3%) [22].
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Palivizumab-resistant variants exhibited a
growth disadvantage compared with parental
viruses and are therefore unlikely to propagate
in the community in the absence of selective
pressure from palivizumab exposure. In
addition, a review of clinical findings among
the children who experienced breakthrough
RSV disease while taking palivizumab did not
reveal an association between mutations in the
RSV F protein gene and RSV disease severity
[69]. However, the clinical impact of transfer or
distribution of palivizumab-resistant mutants is
not clearly understood.
Limitations
There are several limitations of this systematic
review that must be considered. Although
multiple studies and post-marketing
experience involving thousands of high-risk
infants indicate that palivizumab reduces
overall hospitalization rates due to RSV, it is
important to note there are few RCTs and the
majority of the evidence is based on prospective
observational studies/registries. As the
observational studies/registries do not involve
a control arm, they cannot definitively evaluate
the true impact of RSV prophylaxis as
documented in the placebo-controlled
randomized trials [23, 24]. In addition, the
populations in these cohorts may be variable,
as enrollment is based on country-specific
pediatric prophylaxis guidelines and the data
reflect the way in which health care providers
use palivizumab in the real world. Finally, RSV
hospitalization detection rates are influenced by
the hospitalization/ICU threshold changes over
time, changes in bronchiolitis diagnosis over
time, the type of samples collected, and the type
of tests conducted.
CONCLUSION
We conducted a systematic review of published
palivizumab RCT results, prospective, non-
comparative clinical trial results, and
published observational data to describe the
safety, efficacy, and effectiveness of palivizumab
for reducing the risk of serious RSV LRTI disease
in high-risk infants and children. Since
approval in 1998, palivizumab has been used
in more than 80 countries for the passive
prevention of serious RSV disease in high-risk
children, and the patient exposure to
palivizumab has been over 3.2 million
seasonal courses of therapy (data on file,
AbbVie). Compared with placebo, the efficacy
of palivizumab, as measured by a reduction in
the rate of RSV-related hospitalization, depends
on the high-risk groups assessed and varied
from 39% to 82% in subjects with BPD and
CHD and premature infants (B35 weeks GA)
[23, 24, 30]. A meta-analysis of the RSV-related
hospitalization rate from 5 randomized,
placebo-controlled trials yielded an overall OR
of 0.41 (95% CI, 0.31–0.55) in favor of
palivizumab prophylaxis over placebo
(P\0.00001). Palivizumab has shown an
acceptable safety profile, including a low
incidence of anti-palivizumab antibodies in
children with BPD, infants with a history of
prematurity, and children with
hemodynamically significant CHD.
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